DRUG
Albiglutide
30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
Status
Withdrawn
Phase
Phase 3
Enrollment
0
Locations
3
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The incidence of Type 2 Diabetes Mellitus (T2DM) is increasing day by day but the treatment options are limited in children and adolescents. Albiglutide, approved for the treatment of T2DM in adult population, is a novel analogue of glucagon-like peptide-1 (GLP-1) with a sufficiently long half-life to permit once a week injection. The study will be conducted in 2 parts: Part A is a single dose pharmacokinetic (PK) study to confirm the dose and safety of albiglutide in pediatric subjects aged 10 to less than 18 years and Part B is a randomized double-blind placebo controlled study to evaluate the safety and efficacy (glycemic control) of albiglutide in the pediatric population. Treatment duration in Part B is 52 weeks (24 weeks double-blind placebo-controlled and 28 weeks open-label during which all subjects will receive albiglutide). Approximately 210 eligible male and female subjects will be included in the study.
Interventions
Treatment arms and agents.
DRUG
Placebo
Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
Timeline
From registration to results.
First posted
Jan 10, 2017
Study start
Aug 14, 2017
Primary completion
Apr 20, 2020
Study completion
Apr 20, 2020
Results posted
Not reported
Registry updated
Jan 17, 2019
Outcomes
What the study measures.
Primary outcomes
Area under the curve (AUC) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points
Maximum Plasma Concentration (Cmax) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points.
Apparent clearance (CL/F) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points.
Apparent volume of distribution (V/F) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points.
Number of subjects with adverse events (AEs): Part A
Time frame · Up to Week 8 post dose
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. AESI including gastrointestinal events, hypoglycemia, injection site reactions, pancreatitis, medullary thyroid cancer, atrial fibrillation/flutter, and pneumonia etc will also be evaluated.
Change from Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 24: Part B
Time frame · Up to Week 24
Change in HbA1c values from Baseline will be evaluated at Week 24. The superiority of albiglutide over placebo will be assessed.
Time to reach maximum plasma concentration (tmax) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points.
Time to reach half of the maximum plasma concentration (t1/2) of albiglutide: Part A
Time frame · Up to 28 days post-dose
Blood samples will be collected prior to dosing at Baseline and following single-dose administration of albiglutide at indicated time points.
Secondary outcomes
Change from Baseline in fasting Plasma Glucose (FPG): Part B
Time frame · Up to Week 24
FPG will be assessed as a measure of glycemic control.
Percentage of subjects reaching HbA1c less than 7%: Part B
Time frame · Up to Week 24
Subjects reaching HbA1c less than 7% at the end of double-blind phase will be analyzed using logistic regression.
Time to hyperglycemia rescue: Part B
Time frame · Up to Week 24
Time to hyperglycemia rescue will be measured at specific timeframe. Addition of or adjustment to metformin will be the first option for rescue therapy.
Number of subjects with AEs, serious adverse events (SAEs): Part B
Time frame · Up to Week 60
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement will be categorized as SAE. AESI including gastrointestinal events, hypoglycemia, injection site reactions, pancreatitis, medullary thyroid cancer, atrial fibrillation/flutter, and pneumonia etc will be evaluated.
Number of hypoglycemic episodes: Part B
Time frame · Up to Week 60
Hypoglycaemic events as per American Diabetes Association (ADA) criteria: severe hypoglycaemia, documented symptomatic hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia and pseudo hypoglycaemia.
Evaluation of immunogenicity: Part B
Time frame · Up to Week 60
Blood samples will be collected at intervals for the determination of anti-albiglutide antibodies.
Change from Baseline in serum calcitonin levels: Part B
Time frame · Up to Week 52
Blood samples will be collected to measure serum calcitonin.
Number of subjects with abnormal clinical laboratory parameters: Part B
Time frame · Up to Week 60
Hematological, clinical chemistry and urine parameters will be evaluated.
Assessment of Systolic Blood pressure (SBP) and Diastolic Blood Pressure (DBP): Part B
Time frame · Up to Week 60
SBP and DBP will be measured in a seated position after at least a 5-minute rest.
Assessment of pulse rate: Part B
Time frame · Up to Week 60
Pulse rate will be measured in a seated position after at least a 5-minute rest.
Eligibility
Who can take part.
- Minimum age
- 10 Years
- Maximum age
- 17 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Between 10 to less than 18 years of age inclusive at the time of screening. * Diagnosis of T2DM with HbA1c more than or equal to 7.0% \[53 millimole per mole (mmol/mol)\] and less than 10.0% (85.8 mmol/mol) assessed at screening. Currently treated with regimen of diet and exercise with or without metformin. Subjects on metformin monotherapy should have been treated for a minimum of 8 weeks prior to randomization on a dose above 1000 milligram per day (mg/day) or prior documented maximum tolerated dose (MTD) less than or equal to 1000 mg/day. * FPG less than 240 mg/deciliter (dL) at screening. * Fasting C-peptide more than or equal to 0.8 nanogram per milliliter (ng/mL) at screening. * Negative central laboratory assays for Glutamic Acid Decarboxylase 65 (GAD-65) and Islet Cell Autoantigen 512 (ICA512) autoantibodies at screening. * Body weight more than or equal to 30 kilogram (kg) at screening. * Male subjects will be included. Female subjects who have achieved menarche and are of childbearing potential must be practicing adequate contraception for the duration of participation in the study. * Signed informed consent of parent or legal guardian and assent as appropriate will be obtained from the child. Exclusion Criteria: * Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type other than T2DM) * Female subject is pregnant (confirmed by laboratory testing), planning a pregnancy or lactating. * History of cancer that has not been in full remission for at least 3 years before screening. * History of thyroid cancer. * Personal history or family history of thyroid medullary carcinoma or multiple endocrine neoplasia type 2 (MEN2). * History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study (e.g. due to symptomatic gallstones). * Severe gastroparesis within 6 months prior to screening. * History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function. * Have a history of at least one episode of diabetic ketoacidosis (DKA) after receiving anti-diabetic medication. * Fasting triglyceride level more than 750 mg/dL at screening. * Serum calcitonin more than 50 picogram (pg/mL) at screening. * Hemoglobinopathy that may affect determination of HbA1c. * Uncontrolled hypertension at screening. * Estimated Glomerular Filtration Rate (eGFR) less than 90 mL/minute/1.73 meter\^2 (calculated using the Schwartz equation) at screening. * ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin more than 35%) at screening. * Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment). * Current or previous insulin therapy used for more than 4 weeks (continuously) in the 3 months prior to screening. * Use of a GLP-1receptor agonist at study entry and during the study. * Any oral diabetic medications, except metformin, at study entry and during the study. * Use of oral or systemically injected glucocorticoids is generally not allowed within the 3 months before randomization; however, short courses of oral steroids (single dose or multiple doses for up to 7 days) may be permitted provided these cases are discussed with the medical monitor. * Weight loss medications. * Antiretroviral drugs. * Known allergy or serious hypersensitivity reaction to albiglutide or any product components (including yeast and human albumin), any other GLP 1 analogue, insulin, or other study medication's excipients or other contraindications. * Any other reason the investigator deems the subject to be unsuitable for the study or may interfere with trial compliance (e.g. significant medical or psychiatric history). * The subject has participated in a clinical trial and has received an investigational product or device within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Study locations
3 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Morehead City, North Carolina, United States
GSK Investigational Site
El Paso, Texas, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Albiglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University · Cardiovascular Kidney Metabolic Syndrome
Not applicable
Active, not recruiting
23,280,000
2025-09
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen · Diabetes Mellitus, Type 2 · Cardiovascular Diseases
Not applicable
Completed
714,582
2025-06
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · Type2diabetes
Phase 4
Unknown
938
2024-07
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
514
2022-03
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 3
Completed
814
2020-11
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
University of California, San Francisco · Type 2 Diabetes Mellitus
Not applicable
Completed
22
2020-11
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
GlaxoSmithKline · Diabetes Mellitus, Type 2
Phase 4
Terminated
4
2020-10
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.